Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p424 | Other diseases of bone and mineral metabolism | ECTS2016

Bone mineral density changes in kidney transplant recipients

Smalcelj Ruzica

Bone mineral density (BMD) changes were estimated in kidney recipients. In 63 patients aged 24–64 years, measured creatinine clearance at the end of the first posttransplant year was >50 ml/min and remained stable over the study period, bone mineral density (BMD) was estimated in the lumbar spine, femoral neck, Ward’s triangle and the distal third of the radius using dual energy absorptiometry (DEXA) 0.1–4, 12–18 and 23–36 months after transplantat...

ba0005p447 | Other diseases of bone and mineral metabolism | ECTS2016

The characteristics of bone mineral density in men of different ages with type 2 diabetes

Zhen Zhao

Objective: To investigate the characteristics and related factors of bone mineral density (BMD) in men of different ages with type 2 diabetes.Methods: Four hundred and forty four male patients diagnosed with type 2 diabetes and 208 healthy men were involved from 2013 to 2014. The BMD of all men including lumbar spine (L1–L4), femoral neck, trochanter, and total hip were detected using dual-energy X-ray absorptiometry produced by the US company. We g...

ba0005cabs.oc4.5 | Oral Communications | ECTS2016

New models of breast and lung cancer bone metastases for preclinical efficacy testing

Suominen Mari I. , Hagemann Urs B. , Konkol Yvonne , Bernoulli Jenni , Fagerlund Katja M. , Bjerke Roger M. , Karlsson Jenny , Halleen Jussi M. , Cuthbertson Alan

In advanced ER+ve breast cancer, the propensity of bone involvement is 85%. Similarly in advanced lung cancer, 30–40% of patients develop bone metastases, and as recent advances in lung cancer therapies improve survival, the number of patients living with bone metastases is expected to increase. At the same time there is a paucity of especially ER+ and osteoblastic animal models available. We present herein the development of four mouse models of breast and lung cancer su...

ba0005oc6.2 | Development and differentiation (or Aging) | ECTS2016

Bone with uncleavable type I collagen C-propeptide has abnormal development of multiple bone cell populations and increased bone mineral density with age

Barnes Aileen M , Perosky Joseph E , Blouin Stephane , Rajpar M Helen , Khoury Basma , Klaushofer Klaus , Roschger Paul , Fratzl-Zelman Nadja , Kozloff Kenneth M , Marini Joan C

Mutations in the C-propeptide cleavage site of both COL1A1 and COL1A2 cause dominant high bone mass (HBM) osteogenesis imperfecta (OI), characterized by bone hypermineralization. To elucidate the role of C-propeptide processing in bone formation, we generated heterozygous HBM mice in which both residues of the COL1A1 cleavage site were mutated to prevent cleavage by BMP1. HBM mice are smaller than WT in both weight and length and have extremely brittle bones....

ba0005ahp.oc1.2 | Abstract Presentations | ECTS2016

To measure or not to measure? Vitamin D and parathyroid hormone in patients with clinical risk factors for osteoporosis

Bock Oliver , Pyttel Susanne , Dostmann Ute

Background: Despite the large amount of studies published on the association of vitamin D deficiency with higher incidence of falls and fractures, the threshold for a sufficient serum 25(OH)D concentration remains subject to a considerable debate. There has also been no clear consensus on the assessment and treatment of vitamin D deficiency.Objective: To examine the prevalence of vitamin D deficiency and/or insufficiency and its impact on calcium/phospha...

ba0005p306 | Osteoporosis: evaluation and imaging | ECTS2016

To measure or not to measure? Vitamin D and parathyroid hormone in patients with clinical risk factors for osteoporosis

Bock Oliver , Pyttel Susanne , Dostmann Ute

Background: Despite the large amount of studies published on the association of vitamin D deficiency with higher incidence of falls and fractures, the threshold for a sufficient serum 25(OH)D concentration remains subject to a considerable debate. There has also been no clear consensus on the assessment and treatment of vitamin D deficiency.Objective: To examine the prevalence of vitamin D deficiency and/or insufficiency and its impact on calcium/phospha...

ba0001oc5.5 | Treatment of osteoporosis | ECTS2013

Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis

Hattersley Gary , Bilezikian John , Guerriero Jonathan , Kumar Prasanna , Zanchetta Jose , Lyttle C Richard , O'Dea Louis Saint L

A randomized, placebo-controlled phase 2 study evaluated the safety and efficacy of BA058, an analog of hPTHrP(1–34), in postmenopausal women with severe osteoporosis. 221 patients were randomized to received BA058 20, 40, and 80 μg, placebo or teriparatide (TP) 20 μg, by daily s.c. injection. 184 (83%) patients completed an initial 24 weeks of treatment. The mean percent change in lumbar spine BMD at 24 weeks was 1.6% with placebo, 6.7% with BA058 80 μg, a...

ba0001pp349 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Women with hormone sensitive breast cancer who have received chemotherapy including prednisolone have reduced bone mass

Ronn Sofie , Hald Jannie D , Thisted Marianne , Andersen Louise , Gronhoj Louise , Jensen Anders Bonde , Langdahl Bente L

Introduction: Aromatase inhibitors (AI) used as adjuvant treatment of hormone-sensitive breast cancer reduce the level of circulating estrogen and cause accelerated bone loss. The aim of this study is to investigate the prevalence of osteoporosis in women with breast cancer and the effect of chemotherapy on the risk of osteoporosis.Methods: Three hundred and sixty women with hormone-sensitive breast cancer who were scheduled to start treatment with AI we...

ba0002p152 | (1) | ICCBH2013

Zinc supplementation improves bone density in young adults with thalassemia

Fung Ellen B , Kwiatkowski Janet L , Huang James N , Gildengorin Ginny , King Janet C , Queisser Anne C , Vichinsky Elliott P

Poor bone mineralization remains a major health problem in patients with Thal and has been linked to functional zinc deficiency despite adequate dietary intake. The global etiology of poor bone mineralization includes inadequate dietary intake of calcium and vitamin D, endocrinopathies leading to disturbed calcium homeostasis, dysregulation of the GH–IGF1 axis, and delayed puberty, all resulting in limited growth, decreased bone formation and increased bone resorption. Th...